Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


ESMO 2019 Ivosidenib versus placebo in patients with cholangiocarcinoma

Dr. Ghassan Abou-Alfa, medical oncologist at the Memorial Sloan Kettering Cancer Center in New York, presented results of the ClarIDHy-studie at the Presidential symposium. 

  • Sponsors

    This program is editorially independent and is financially supported by:

Related items

Congress news 10/10/2019

ESMO 2019 Veliparib with carboplatin and paclitaxel in HER2-negative breast cancer

At this ESMO congress, medical oncologist Véronique Diéras presented a late breaking abstract on the BROCADE-3 trial. In this trial the effectivity and tolerability of veliparib with chemotherapy was investigated in patients with BRCA-positive HER2-negatieve breast cancer. In this interview, Dr. Diéras summarizes the main findings.

Congress news 10/10/2019

ESMO 2019 Osimertinib as first-line treatment for NSCLC: final OS analysis

The FLAURA-studie compares the effectivity of the EGFR tyrosine kinase inhibitor (EGFR-TKI) osimertinib to the EGFR-TKI's gefitinib of erlotinib in NSCLC. In 2018, benefit in progression-free survival was reported for osimertinib. At this ESMO congress, dr. Suresh Ramalingam (Winship Cancer Institute of Emory University), presented the results on overall survival.

Congress news 08/10/2019

ESMO 2019 Analysis of tumor hyperprogression with nivolumab in RCTs

Pulmonologist prof. Martin Reck from the LungenClinic Großhansdorf in Germany presented results on a relatively new phenomenon: tumor hyperprogression after treatment with immunotherapy. In the CheckMate 451 cohort, the occurence of this phenomenon with nivolumab-treated es-SCLC patients was evaluated.

Congress news 01/10/2019

ESMO 2019 Highlights Breastcancer

Prof. Guy Jerusalem, MD, PhD, medical oncologist at the CHU de Liège in Belgium, shares his view on the most important ESMO news for breastcancer.